| Generic name | Vemurafenib |
| Brand name(s), other common name(s) | Zelboraf® |
| Drug type | Kinase inhibitor |
| How the drug is given | By mouth |
Indications and Usage
Vemurafenib (Zelboraf®) is FDA approved for the treatment of patients with Erdheim-Chester Disease (ECD) with BRAF V600 mutation.
Side effects needing medical attention
Joint pain, a flat or raised red bump on the skin (rash maculo-papular), hair loss (alopecia), fatigue, electrocardiogram QT interval prolonged, and benign, sometimes multiple, tumors caused by viruses (skin papilloma).
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.